Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors inside the central nervous system, conolidine modulates alternate molecular targets. A Science Innovations study found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://billd430egi2.ssnblog.com/profile